BofA raised the firm’s price target on Abbott (ABT) to $150 from $133 and keeps a Buy rating on the shares. Given the current premium, the firm thinks “there’s probably not a lot of room left” on the multiple, arguing that upside from here is dependent on double digit EPS growth and M&A. The firm moved its valuation year from 2025 EPS to 2026 EPS, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT: